An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Eribulin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-150
- Sponsors Eisai Inc
- 29 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2018.
- 15 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2019.
- 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History